Second infliximab biosimilar on its way

The PBAC has recommended the listing of a second biosimilar to infliximab (Remicade). A year after Pfizer’s biosimilar (Inflectra) gained PBS listing MSD’s biosimilar Renflexis is now recommended by the PBAC on a cost minimisation basis with infliximab (Remicade) for all indications – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, Crohn’s disease, fistulating ...

Already a member?

Login to keep reading.

© 2021 the limbic